Androclus Therapeutics to Present at Windhover Information's ``The Start-Up Forum 2005''.

SAN DIEGO & MILAN, Italy -- Androclus Therapeutics has announced that it will be present at Windhover Information's "The Start-Up Forum 2005", taking place May 18-20, 2005 at the Cambridge Marriott in Boston, MA. Igor P. Bilinsky, chief executive officer of Androclus Therapeutics Inc., will present at 4:15 pm EDT on May 19, 2005.

About Androclus Therapeutics

Androclus Therapeutics is a private clinical stage biotechnology company developing a breakthrough technology platform and novel therapeutics for the treatment of autoimmune and inflammatory diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS) and inflammatory bowel disease (IBD).

Androclus' leading drug candidate is an orally administered peptide AT-001 (dnaJP1) for the treatment of RA. AT-001 is currently in a Phase II clinical trial that will be completed in Q3 2005. A previously completed open-label Phase I/IIa demonstrated safety, biological efficacy and trends of clinical efficacy. Androclus has partnered AT-001 with a large biotechnology company.

Building on the experience with AT-001 and using the same technology platform, Androclus is developing orally administered therapeutic peptides for the treatment of MS and IBD, with INDs for both indications expected within one year.

Compared to existing biologics for the treatment of autoimmune diseases, Androclus' drug candidates are expected to offer a complementary approach, be more selective in targeting autoimmune inflammation, have a better safety profile and a more convenient oral route of administration.

Androclus plans to raise the next financing round in Q4 2005, to follow an announcement of AT-001 Phase II results. The proceeds will be used for clinical development of MS and IBD drug candidates, advancement of the technology platform and building a deep discovery pipeline.